MARKET

ABIO

ABIO

ARCA BIOPHARMA
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.980
-0.140
-3.40%
After Hours: 4.020 +0.04 +1.01% 17:51 03/08 EST
OPEN
4.184
PREV CLOSE
4.120
HIGH
4.190
LOW
3.930
VOLUME
877.38K
TURNOVER
--
52 WEEK HIGH
22.00
52 WEEK LOW
2.210
MARKET CAP
37.10M
P/E (TTM)
-1.5014
1D
5D
1M
3M
1Y
5Y
Atrial Fibrillation Competitive Landscape,2020: Emerging Therapies and Key pharma players involved
Feb 25, 2021 (AB Digital via COMTEX) -- "Atrial Fibrillation Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present...
ABNewswire · 02/25 23:49
3 Net-Net Working Capital Stocks
GuruFocus News · 02/16 22:07
3 Net-Net Working Capital Stocks
3 Net-Net Working Capital Stocks, Stocks: ATHA,ABIO,MTCR, release date:Feb 16, 2021
GuruFocus.com · 02/16 15:21
Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Simply Wall St. · 02/13 06:09
Atrial Fibrillation Drugs Industry Research Report 2021 by Type, Applications, Regions, Market Size Estimation and Forecast to 2025
The Express Wire · 01/27 09:22
Best Penny Stocks To Buy Right Now? 5 For Your January Watch List
Jan 19, 2021 (Penny Stocks via COMTEX) -- Penny Stocks Continue Captivating The Market If you look at the top 10 most active stocks in the market today by...
Penny Stocks · 01/19 20:47
The impact of COVID-19 on Atrial Fibrillation Drugs Market - Growth, Trends, Industry Outlook, Growth Opportunity, Business Growth And Forecast (2021 - 2026)
Jan 12, 2021 (The Expresswire) -- The Atrial Fibrillation Drugs market report provides a detailed analysis of global market size, regional and country-level...
The Express Wire · 01/12 05:45
ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the first patients have been enrolled in ASPEN-COVID-19, ...
GlobeNewswire · 12/15/2020 13:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ABIO. Analyze the recent business situations of ARCA BIOPHARMA through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ABIO stock price target is 7.00 with a high estimate of 7.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 35
Institutional Holdings: 958.13K
% Owned: 10.28%
Shares Outstanding: 9.32M
TypeInstitutionsShares
Increased
4
241.47K
New
15
167.68K
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.16%
Pharmaceuticals & Medical Research
-0.50%
Key Executives
Chairman/Director
Robert Conway
Chief Executive Officer/President/Director
Michael Bristow
Chief Operating Officer
Thomas Keuer
Senior Vice President/General Counsel/Secretary
Christopher Ozeroff
Chief Accounting Officer/Vice President - Finance
Brian Selby
Lead Director
Linda Grais
Director
Anders Hove
Director
Daniel Mitchell
Director
Raymond Woosley
No Data
About ABIO
ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.

Webull offers kinds of Arca Biopharma Inc stock information, including NASDAQ:ABIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABIO stock methods without spending real money on the virtual paper trading platform.